The development of effective therapies for Aniridia is a complex and multifaceted endeavor. As a research services provider, Protheragen is committed to providing comprehensive Aniridia diagnostics and therapeutic development solutions.
Aniridia is a rare genetic ocular disorder characterized by the underdevelopment or absence of the iris, leading to significant visual impairments. The condition is primarily caused by mutations in the PAX6 gene, which plays a crucial role in ocular development. Aniridia is associated with a range of complications, including Aniridia-Associated Keratopathy (AAK), glaucoma, cataracts, and dry eye disease, which collectively contribute to the deterioration of visual function.
Fig.1 Schematic drawing showing the development of aniridia-associated keratopathy (AAK). (Landsend E. C., et al., 2021)The PAX6 gene, located on chromosome 11p13, encodes a transcription factor essential for the development of the eye, brain, and other organs. Mutations in PAX6 result in a spectrum of phenotypic expressions, from mild iris hypoplasia to complete absence of the iris. The genetic heterogeneity of Aniridia contributes to the variability in disease presentation, with over 500 unique heterozygous loss-of-function mutations reported.
Pharmacological Therapies
Pharmacological approaches focus on modulating inflammation, neovascularization, and tear abnormalities. Anti-VEGF compounds, such as Bevacizumab, have shown promise in reducing corneal neovascularization and delaying AAK progression. Additionally, autologous serum eye drops and amniotic membrane-derived eye drops are being explored for their potential to stabilize the ocular surface and reduce inflammation.
Cell and Gene Therapies
Cell therapy, including limbal stem cell transplantation and the use of alternative cell sources like oral mucosal epithelial cells, aims to restore the corneal epithelium and improve visual outcomes. Gene therapy, while still in preclinical stages for Aniridia, offers a potential long-term solution by correcting the underlying genetic mutation. CRISPR/Cas9-based gene editing has demonstrated the potential to correct PAX6 mutations in animal models, opening new avenues for therapeutic development.
By leveraging our extensive expertise and state-of-the-art capabilities, Protheragen is at the forefront of Aniridia therapeutics development, offering a comprehensive suite of services to accelerate the discovery and development of novel therapeutics.
Protheragen offers high-throughput and high-content screening services to identify and optimize candidate therapeutics targeting PAX6 haploinsufficiency. Services include screening of TRIDs, small-molecule agonists, and gene therapy vectors using patient-derived iPSC models, including 3D optic cups and LESC cultures. We quantify PAX6 protein restoration via Western blotting and immunofluorescence, and assess phenotypic rescue by measuring VSX2 normalization, LESC marker expression (ABCG2, SOX10), and epithelial cell proliferation. For TRID screening, we evaluate compounds such as amlexanox, ataluren, and 2,6-diaminopurine, comparing their ability to bypass PTCs and restore full-length PAX6 expression in mutation-specific models.
We conduct comprehensive efficacy studies using validated in vitro and in vivo aniridia models to evaluate therapeutic candidates. In vitro assessments utilize iPSC-derived optic cups and corneal organoids to measure improvements in ocular tissue architecture, neural differentiation, and limbal stem cell function. In vivo studies employ Pax6<sup Sey/ mouse models, assessing therapeutic effects on iris development, corneal transparency, and AAK progression via histopathology, immunohistochemistry, and optical coherence tomography (OCT). Functional endpoints include electroretinography (ERG) to quantify rod/cone response recovery and optokinetic tracking to evaluate visual function, mirroring translational endpoints for clinical trials.
Protheragen provides specialized support for aniridia gene therapy development, focusing on vector design, optimization, and preclinical validation. Services include design and engineering of adeno-associated virus (AAV) vectors tailored for ocular tissue targeting—including corneal epithelium, retina, and limbus—and assessment of transduction efficiency in iPSC-derived models and mouse ocular tissues. For CRISPR/Cas9-based therapies, we offer guide RNA design to correct PAX6 nonsense or missense mutations, off-target effect screening via whole-genome sequencing, and validation of mutation correction in patient iPSCs. We also evaluate vector safety, including immunogenicity and off-target genomic effects, in preclinical models.
Our PK/PD services are optimized for ocular therapeutics, evaluating drug distribution, metabolism, and pharmacological effects in relevant tissues. PK studies measure compound concentrations in aqueous humor, vitreous, corneal tissue, and retina using liquid chromatography-mass spectrometry (LC-MS/MS), with a focus on blood-ocular barrier penetration and local retention. PD assessments include quantification of PAX6 pathway activation (via GLI1, PTCH1 expression), corneal neovascularization reduction, and LESC function restoration. We conduct dose-ranging studies to establish optimal dosing regimens for topical, systemic, or intravitreal administration, and identify concentration-response relationships to support clinical dose selection.
We offer biomarker discovery and validation services to identify surrogate endpoints for aniridia therapeutic development. Using RNA sequencing and single-cell analysis, we characterize molecular signatures of aniridia, including PAX6 target gene expression (VSX2, FOXC1, TGFβ2) and LESC dysfunction markers. We validate candidate biomarkers—such as ABCG2, SOX10, and PAX6 protein levels—for use in efficacy assessment, utilizing immunohistochemistry, qPCR, and flow cytometry. Additionally, we develop imaging-based biomarkers, including OCT metrics of corneal thickness and ERG parameters, to enable non-invasive monitoring of therapeutic effects in preclinical models.
Protheragen's toxicology services ensure candidate therapeutics meet preclinical safety requirements for ocular administration. In vitro toxicity testing uses iPSC-derived corneal epithelial cells and retinal organoids to evaluate cytotoxicity, genotoxicity, and effects on neural differentiation. In vivo studies in rodent models assess acute and subchronic toxicity of topical, intravitreal, or systemic therapies, monitoring clinical signs, intraocular pressure, and histopathological changes in the cornea, retina, and optic nerve. For gene therapies, we evaluate immune responses to viral vectors—including antibody production—and potential off-target effects in ocular and systemic tissues, ensuring safety profiles align with regulatory guidelines.
We specialize in developing and validating patient-derived aniridia models tailored to specific genetic mutations. Services include iPSC derivation from patient fibroblasts or blood samples, pluripotency characterization, and differentiation into disease-relevant ocular tissues—optic cups, corneal organoids, and LESC cultures. We validate models by confirming key aniridia phenotypes, including reduced PAX6 expression, abnormal epithelial organization, and LESC deficiency. These mutation-specific models enable personalized therapeutic testing, supporting the development of precision medicines for distinct aniridia subtypes and enhancing translation to clinical efficacy.
Our preclinical research services encompass a range of capabilities, from target identification and validation to the development of therapeutic candidates. We leverage cutting-edge technologies and methodologies to evaluate the safety and efficacy of new drugs and therapies in relevant animal models. If you are interested in our services, please feel free to contact us.
References
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
As a research service provider, Protehragen offers a comprehensive range of cutting-edge services to advance the development of innovative therapies and unlock the future of rare eye disease therapeutics.
Congenital Ophthalmic Diseases
Hereditary Ophthalmic Diseases
Infectious Ophthalmic Diseases
Copyright © Protheragen. All rights reserved.
